Monoclonal antibodies reactive with tumor associated antigens are being studied for their utility for cancer therapy, either alone as an immunologic mediator of cytotoxicity, or conjugated to a drug, toxin, or radionuclide. A significant problem with radiolabeled MAbs is their relative inaccessibility to all regions of a tumor in adequate quantities. Because of the large size of the MAb-conjugates, endothelial and reticuloendothelial tissues act as restrictive barriers limiting the egress from the intravascular space of these large molecules. For this reason, the ability to transiently increase vascular permeability is receiving considerable attention as a way of enhancing tumor uptake of highly specific MAbs from the blood. The investigators involved in this research initiative have developed a panel of stable conformationally constrained decapeptide agonists corresponding to the C-terminal """"""""effector"""""""" region of human C5a that have the ability to increase vascular permeability. This project will investigate methods of conjugation of the C5a decapeptides to MAb B72.3 without loss of the vasoactivity of the agonist peptides or the specificity/ avidity of the MAb. Furthermore, the in vivo use of the Mab-C5a peptide constructs will be studied to determine the optimal decapeptide and linker combination to improve the tumor distribution of radiolabeled MAbs. These studies will lead to the preparation of clinical grade materials for future clinical radioimmunotherapy studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Chan, June M; Gong, Zhihong; Holly, Elizabeth A et al. (2013) Dietary patterns and risk of pancreatic cancer in a large population-based case-control study in the San Francisco Bay Area. Nutr Cancer 65:157-64
Mutolo, Michael J; Morris, Kirsten J; Leir, Shih-Hsing et al. (2012) Tumor suppression by collagen XV is independent of the restin domain. Matrix Biol 31:285-9
Pour, Parviz M (2012) A novel tissue for islet transplantation in diabetics. Pancreatology 12:57-60
Sherman, Simon; Shats, Oleg; Ketcham, Marsha A et al. (2011) PCCR: Pancreatic Cancer Collaborative Registry. Cancer Inform 10:83-91
Chan, June M; Wang, Furong; Holly, Elizabeth A (2009) Sweets, sweetened beverages, and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control 20:835-46
Moniaux, Nicolas; Nemos, Christophe; Deb, Shonali et al. (2009) The human RNA polymerase II-associated factor 1 (hPaf1): a new regulator of cell-cycle progression. PLoS One 4:e7077
Mimeault, M; Hauke, R; Batra, S K (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673-91
Hennig, R; Osman, T; Esposito, I et al. (2008) BLT2 is expressed in PanINs, IPMNs, pancreatic cancer and stimulates tumour cell proliferation. Br J Cancer 99:1064-73
Davda, Jasmine P; Jain, Maneesh; Batra, Surinder K et al. (2008) A physiologically based pharmacokinetic (PBPK) model to characterize and predict the disposition of monoclonal antibody CC49 and its single chain Fv constructs. Int Immunopharmacol 8:401-13
Hennig, Rene; Kehl, Timo; Noor, Seema et al. (2007) 15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth. Neoplasia 9:917-26

Showing the most recent 10 out of 108 publications